Бюллетень сибирской медицины (Apr 2020)

Experimental estimation of the effects of exogenous carbon monoxide on blood cells

  • I. V. Petrova,
  • J. G. Birulina,
  • O. A. Trubacheva,
  • S. N. Belyaeva,
  • O. L. Shnaider,
  • A. V. Nosarev,
  • S. V. Gusakova,
  • V. N. Vasilev,
  • G. A. Suhanova

DOI
https://doi.org/10.20538/1682-0363-2020-1-94-100
Journal volume & issue
Vol. 19, no. 1
pp. 94 – 100

Abstract

Read online

The aim of the study was to investigate the effect of the carbon monoxide (CO) donor on the Ca2+-activated potassium permeability of the erythrocyte membrane and platelet aggregation ability.Materials and methods. Healthy volunteers (n = 27) and patients with chronic coronary heart disease (CHD) (n = 32) of both sexes were examined. The material of the study was packed red blood cells and platelet-rich plasma obtained from patient’s venous blood. The change of Ca2+-dependent potassium conductivity of the erythrocyte membrane was evaluated by potentiometric method, and the platelet aggregation was studied by turbidimetric method. Carbon monoxide releasing molecule-2 (CORM-2) was used as a CO donor. The amplitude of A23187- and redox-induced hyperpolarization response (HR) of erythrocytes, and the rate and degree of platelet aggregation were estimated.Results. It was shown that the addition of CORM-2 (10 and 100 μM) in the erythrocyte suspension caused a dose-dependent decrease in the amplitude of A23187- and redox-dependent HR in healthy donors, as well as in patients with chronic CHD. The maximum decrease was observed in the presence of 100 μM CORM-2. The effect of CORM-2 at concentrations of 10 and 100 μM on collagen-induced platelet aggregation led to a decrease in the degree and rate of aggregation in healthy donors. The maximum effect was shown at 100 μM of CO donor. However, such an unambiguous effect of CORM-2 on the aggregation parameters in patients with CHD was not observed.Conclusion. The results suggest that CO has a significant effect on the ion transport function of the erythrocyte membrane and platelet aggregation activity of both healthy donors and patients with CHD.

Keywords